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Abstract
Background:  Diabetes  Mellitus  (DM)  is  a  rampantly  growing 
epidemic in the United States, affecting nearly 10% of the adult 
population. Studies have shown that higher levels of Total Biliru-
bin (TBili) convey a protective effect with regard to cardiovascular 
risk. In this study, we will examine the relationship between TBili 
level and prevalence of DM to discern whether a similar relation-
ship exists.
Methods: The National Health and  Nutrition Examination Sur-
vey (NHANES) is a comprehensive survey performed regularly to 
evaluate the overall health and nutrition status of the United States 
population. For the purpose of this study, we combined NHANES 
data collected between 1999 and 2006. Totally 15,876 eligible par-
ticipants were selected after excluding all patients younger than 
twenty years, those with a history of abnormal liver function tests, 
or those who disclosed a history of liver disease. The data collected 
on these individuals was adjusted for demographic characteristics, 
as well as risk factors for DM, and was analyzed via multivariate 
logistic regression, using SAS proc survey methodology.
Results: After age adjustment, increased TBili was associated with 
26% reduction in diabetes risk (OR 0.74, 95% CI 0.64 - 0.88). Mul-
tivariate analysis, adjusting for all diabetes risk factors assessed, 
confirmed this association (OR 0.80, 95% CI 0.67 - 0.95).
Conclusions: Our results show that a higher level of serum TBili 
is associated with odds of having a lower incidence of DM. This 
finding supports the hypothesis that the antioxidant nature of TBili, 
demonstrating a protective effect with regard to the risk of stroke, 
atherosclerosis, and vasculitis in prior research, also extends to DM 
risk. Furthermore, research has shown that higher levels of TBili in-
crease glucose mobilization into the cells, leading to more efficient, 
biologic glucose utilization. There is no doubt that the beneficial 
effect of TBili is multifactorial; thus further investigation is war-
ranted.
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Introduction
Diabetes Mellitus has become an epidemic throughout the 
world. Prevalence data, collected in 2007, indicate that 7.8% 
of the population have been diagnosed with this disease [1]. 
From a fiscal standpoint, the diagnosis of Diabetes Mellitus 
is associated with a two-fold rise in medical cost, equaling 
approximately  $116  billion  dollars  in  direct  expenditures 
and $58 million in indirect expenditures, in the United States 
(US) [1]. Given this disease’s dramatic impact on the physi-
cal and financial health of the US population, disease pre-
vention has taken on paramount importance. With this focus 
in mind, research activity has focused on finding physiologic 
factors that decrease a person’s risk of developing Diabetes 
Mellitus.
Bilirubin has been conjectured to be one such factor. 
There is a growing body of literature which shows that high-
er Total Bilirubin levels (TBili) are protective against car-
diovascular disease, Stroke and Peripheral Arterial Disease 
[2-7]. Studies suggest that an increased expression of Heme 
Oxygenase, an enzyme used to break down the hemoglobin 
into bilirubin, is associated with enhanced insulin sensitiv-
ity and glucose metabolism, thus resulting in greater rates 
of rat model euglycemia [8, 9]. Furthermore, the antioxidant 
properties of TBili have been postulated to reverse oxidative 
damage associated with a hyperglycemic state [10]. Con-
sequently, we have undertaken this population-based study 
to assess whether higher levels of TBili, within the physi-
ologically normal range, convey a decreased risk of Diabetes 
Mellitus in the US population.
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Materials and Methods
The  National  Health  and  Nutrition  Examination  Survey 
(NHANES) is a nation-wide survey performed jointly by 
the National Center for Health Statistics and the Center for 
Disease Control and Prevention (CDC), on a representative 
sample of the United States (US) population. This sample 
is chosen using a stratified, multistage probability cluster 
sampling design of the non-institutionalized, non-military 
US  population  [11].  Components  of  this  survey  include 
questionnaires about demographics and health status, gen-
eral medical examinations, as well as laboratory tests of var-
ied bodily fluids. The physical examination component of 
NHANES consists of medical, dental, AND anthropometri-
cal measurements collected by trained personnel [12].
For the purpose of our study, we examined NHANES 
data collected between 1999 and 2006. Exclusion criteria in 
our protocol removed all data for NHANES participants who 
were younger than twenty years-of-age, who reported a his-
tory of liver disease, who had abnormal liver function studies, 
or who had missing data values. Of 41,474 participants who 
had data collected during our seven-year period-of-interest, 
15,876 did not meet any of the exclusion criteria. Based on 
previous studies we stratified TBili into two groups. One had 
the TBili level of less than 10 micromol/L and the other had a 
level of greater than or equal to 10 micromol/L [2, 23]. 
Laboratory methods
To measure total Bilirubin, NHANES used the LX20 process 
which utilizes a timed endpoint Diazo method. The basis of 
this method is formation of Azobilrubin from a reaction with 
a Diazo reagent. The change in the absorbance level of the 
reagent is measured, as this value is directly proportional to 
the concentration of Bilirubin. Fasting blood sugar was mea-
sured using Roche/Hitachi 911 instrument (Roche Diagnos-
tics, Indianapolis) on early morning serum sample, for which 
subjects  were asked to fast for nine hours. [11].  
Case definition
Case definition of Diabetes Mellitus was based on fasting 
blood sugar value of not less than 126 mg/dl (7.0 mmol/L) 
and the participant’s response to the following questions: (1) 
‘Other than during pregnancy, have you ever been told by a 
doctor or other health professional that you have diabetes or 
sugar diabetes?’; (2) ‘Are you taking insulin now?’; (3) ‘Are 
you taking any pills to decrease your blood sugar?’.
Definition of covariables
The NHANES questionnaire section was used for the char-
acterization of age, sex, race, tobacco use pattern, alcohol 
use, highest level of education achieved, and marital status. 
Hypertension was defined as a mean systolic blood pressure 
of 140 mm Hg, a mean diastolic blood pressure of 90 mm 
Hg, or reporting a physician diagnosis of high blood pres-
sure. Total cholesterol was defined as reporting that a phy-
sician had diagnosed that person with high cholesterol or 
reporting that a physician had advised that person to take 
cholesterol lowering medications. Prevalent cardiovascular 
disease was defined as a self-reported history of coronary 
heart disease, previous heart attack, or history of stroke. BMI 
was categorized into the three categories of normal, over-
weight and obese based on CDC guidelines [13].
 
Statistical analysis
In  order  to  account  for  the  complex,  stratified,  multi-
stage probability cluster sampling design employed in the 
NHANES survey, we analyzed this data using SAS version 
9.1’s (Cary, North Carolina) Proc Survey methodology. Vari-
ance was estimated using the jackknife replacement method. 
We calculated the age-adjusted prevalence estimates, strati-
fied by demographics and pre-determined risk factors. We 
used proc survey logistic regression to create a risk-factor 
based model, and calculated odds ratios with 95% confi-
dence  Intervals.  These  models  were  specifically  adjusted 
for age, sex, race, smoking, alcohol, education and marital 
status.
 
Results
The bilirubin levels in the sample population were normally 
distributed, with a small right sided tail (Fig. 1). The mean 
TBili level was 11.89 micromol/L, with a standard deviation 
Figure 1. Distribution of Bilirubin (TBili) levels in the target popula-
tion.
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of 5.31. 
The demographic variables of the two groups were com-
pared by age adjusted prevalence (Table 1). A greater propor-
tion of men were found to have a serum TBili level above 
10 micromol/L. For individuals who had Diabetes Mellitus, 
70.45% (SE = 0.86) had a TBili level of 10 micromol/L. Fur-
thermore, a statistically-significant, unadjusted association 
between higher TBili level and Diabetes did exist (OR: 0.74, 
95% CI: 0.64 - 0.88). The relationship remained significant, 
after adjusting for age, sex, race, married status, education, 
BMI and smoking (OR: 0.80, 95% CI: 0.67 - 0.95) (Fig. 2 
and 3).
Discussion
  
Our study supports the notion that people with high TBili 
have lesser odds of prevalence of Diabetes Mellitus (DMI 
and DMII). This is in keeping with previously reported stud-
ies which have shown higher TBili levels to be protective 
against Coronary Artery Disease, Stroke and Peripheral Vas-
cular Disease [2-7].  
Bilirubin has been regarded as a powerful endogenous 
anti-oxidant and anti- inflammatory agent [14-18]. Thus, it 
stands to reason that higher TBili levels may be protective 
against the autoimmune, inflammation-related pathology of 
type 1 diabetes and oxidative physiologic stress associated 
with development of type 2 diabetes [19].  Current research 
also suggests that physiological levels of TBili block the pro-
duction of various free radicals that might hinder the inhibi-
tory responses of the cell to take up the high glucose [20]. 
Furthermore, it is shown to prevent the vascular endothelial 
activation from the oxidative stress in the vessels [21, 22].   
In addition, rat model studies of DM II have shown that 
 
Serum TBili
< 10 micromole/liter 
 
Serum TBili
≥ 10 micromole/liter
Age    20 - 39 32.28%   SE 1.18 67.72%   SE 1.18
           40 - 59 28.93%   SE 0.93 71.07%   SE 0.93
           60 and above 27.43%   SE 1.15 72.57%   SE 1.15
Male  17.83%   SE 0.80 82.16%   SE 0.80
Female 40.45%   SE 1.04 59.55%   SE 1.04
Edu < High school 37.09%   SE 1.39 62.91%   SE 1.39
Edu > High school 28.21%   SE 0.81 71.79%   SE 0.81
Non-black 28.82%   SE 0.86 71.18%   SE 0.86
Black 39.01%   SE 2.01 60.94%   SE 2.01
Non smoker 28.51%   SE 0.95 71.49%   SE 0.95
Smoking 31.34%   SE 1.02 68.66%   SE 1.02
No alcohol consumption 28.98%   SE 1.20 71.02%   SE 1.20
Moderate alcohol consumption 28.36%   SE 1.16 71.64%   SE 1.16
Heavy alcohol consumption 32.12%   SE 1.02 67.89%   SE 1.02
Low triclycerides 28.87%   SE 0.79 71.13%   SE 0.79
High triclycerides 32.13%   SE 1.23 67.87%   SE 1.23
Lower waist circumference 25.52%   SE 0.86 74.48%   SE 0.86
Higher waist circumference 34.30%   SE 1.05 65.70%   SE 1.05
BMI     less than 25 28.14%   SE 1.01 71.86%   SE 1.01
             25 - 29 27.11%   SE 1.02 72.89%   SE 1.02
             30 and above 35.00%   SE 1.21 65.00%   SE 1.01
Table 1. Demographic Characteristics (Age Adjusted Prevalence)
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increased  expression  of  Heme  Oxygenase-1,  the  enzyme 
responsible for conversion of Hemoglobin to Bilirubin, is 
associated with enhanced insulin sensitivity and glucose me-
tabolism resulting in greater rates of rat model euglycemia. 
Moreover, Hemin, an activator of the Heme Oxygenase sys-
tem, has been found to increase the expression of GLUT-4 
receptors and Adiponectin, a hormone which increases insu-
lin sensitivity [20]. Similar to TBili, and in light of its anti-
inflammatory  properties,  higher  Adiponectin  levels  have 
been associated with lower DM prevalence. However, unlike 
Adiponectin since TBili is a commonly measured laboratory 
value, measuring TBili levels would offer a cost-effective 
method of DM risk stratification..  
This study follows a complex sampling with the provi-
sion of the weights, which makes it more realistic to project 
on to the United States population. The amalgamation of 
four large cross sectional surveys done on the representative 
population of the United States from 1999 to 2006 translated 
this study high volume population based study. So we got a 
fair amount of population who have diabetes and who didn’t. 
The stratification of total bilirubin into 2 groups, one having 
a TBili level of less than 10 micromol/L and the other having 
the TBili level of greater than or equal to 10 millimol/L is 
based on previous study which showed that a level of TBili 
equal to or above 10 millimol/L is cardio protective [23].
Another interesting observation is that there is a greater 
Figure 3. Comparing the adjusted odds ratio of having Diabetes in TBili < 10 and Tbili 
≥10 groups.
Figure 2. Prevalence of TBili values in patients with Diabetes and No Diabetes.
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distribution of population in the higher TBili group which 
had the bilirubin greater or equal to 10 micromol/L, which 
was nearly consistent in all demographic groups. Needless 
to say also there is most of the population distribution in the 
latter group (≥ 10 micromol/L) with respect to prevalence of 
diabetes and prevalence of ‘no diabetes’ (66.1% vs 33.8% of 
diabetes group and 70.5% vs 29.5% of ‘no diabetes’ group.   
Our use of population-adjusted data from a national sur-
vey, using predetermined definition is not without its limita-
tions. One major limitation to this study is that the definition 
of Diabetes Mellitus is predicated on subject recollection 
and self reported diagnosis, thus introducing a component of 
recall bias. In order to compensate for this, we have added 
fasting blood sugar measurements into our study’s definition 
of Diabetes Mellitus.  
For similar reasons, our study is limited in its ability to 
determine whether the protective effects of TBili are limited 
to only one form of Diabetes Mellitus, or whether the protec-
tive effect influences the incidence and prevalence of both 
DM type1 and type 2. Also, the cross sectional nature of the 
data derived from NHAHES’s methodology hinders deter-
mination of a temporal association or the cause-and-effect 
between TBili and development of DM type 1 or type 2. The 
lack of fractionation of TBili also limits our ability to deter-
mine whether it is the indirect fraction, the direct fraction, 
or a combined effect of the varied fractions of TBili, which 
convey the protective effect we described in this study [24].
In conclusion, there appears to be a beneficial effect of 
TBili on Diabetes. Further investigation is warranted in or-
der to delineate whether this protective phenomenon extends 
to all forms of Diabetes Mellitus, whether it is conveyed by 
both Indirect and Direct Bilirubin, and what avenues are 
available to therapeutically raise an at-risk patient’s bilirubin 
levels for optimal protection from this dreaded disease.
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